NCT05079425

A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect After the Oral Administration of NXC736 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: NEXTGEN Bioscience · Industry
• Sex: Male
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo- controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NXC736 after oral administration in healthy male volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	NXC736	Oral administration
DRUG	Placebo	Oral administration

Timeline

• Start date: 2021-09-01
• Primary completion: 2022-11-01
• Completion: 2022-11-01
• First posted: 2021-10-15
• Last updated: 2023-02-08

Locations

1 site across 1 country: South Korea